Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors

Ticagrelor currently represents the most tested and commonly used P2Y12 inhibitor monotherapy following percutaneous coronary intervention. The purpose of this study is to conduct a head-to-head comparison on the pharmacodynamic efficacy of ticagrelor-based and prasugrel-based single antiplatelet therapy. To determine if the PD profiles of ticagrelor- and prasugrel-based SAPT are comparable, we aim to conduct a non-inferiority study between the two strategies.

NCT Number	NCT06691191
Lead Sponsor	University of Florida
Conditions	Coronary Artery Disease
Enrollment	48 participants
Start Date	2025-01-08
Primary Completion	2026-08-31 (estimated)
Study Completion	2026-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-02-05